MERGERS & ACQUISITIONS
Pfizer Buys King Pharmaceuticals for $3.6 Billion
Pharmaceutical firm Pfizer will acquire all outstanding stock and stock equivalents of King Pharmaceuticals, according to terms of the deal announced Oct. 12. Totaling $3.6 billion, the acquisition represents an effort by Pfizer to expand its business in the pain medication sector. Lawyers from Covington & Burling...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In